Article Sidebar

pdf
Date Published: 12/08/2025
Abstract Views: 249
Views pdf: 72
DOI: https://doi.org/10.51298/vmj.v552i3.15147
Issue
Vol. 552 No. 3 (2025)
Section
Các bài báo
How to Cite
Nguyễn Xuân, H., Nguyễn Xuân, H., Nguyễn Nhật, T., & Lê Văn, Q. (2025). TREATMENT OUTCOMES OF TRANSORAL ENDOSCOPIC THYROIDECTOMY FOR DIFFERENTIATED THYROID CANCER CT1N0M0 AT HANOI MEDICAL UNIVERSITY HOSPITAL. Vietnam Medical Journal, 552(3). https://doi.org/10.51298/vmj.v552i3.15147

TREATMENT OUTCOMES OF TRANSORAL ENDOSCOPIC THYROIDECTOMY FOR DIFFERENTIATED THYROID CANCER CT1N0M0 AT HANOI MEDICAL UNIVERSITY HOSPITAL

Hiền Nguyễn Xuân, Hậu Nguyễn Xuân, Tân Nguyễn Nhật, Quảng Lê Văn

Main Article Content

Abstract

Objective: To describe the clinicopathological characteristics and treatment outcomes of patients with stage cT1N0M0 differentiated thyroid carcinoma (DTC) managed with the transoral endoscopic thyroidectomy vestibular approach (TOETVA) at Hanoi Medical University Hospital. Materials and Methods: This descriptive longitudinal study included 270 patients with stage cT1N0M0 DTC who underwent TOETVA between January 2019 and December 2024. Results: Women comprised 84.8% of the cohort, with a mean age of 34.8 ± 8.1 years. The mean tumor diameter was 7.2 ± 3.2mm. Occult central lymph-node metastasis was identified post-operatively in 42.6% of patients. After a mean follow-up of 30.6 ± 13.5 months, the 3-year disease-free survival rate was 96.7%. Conclusion: TOETVA is a safe and effective surgical option for patients with stage cT1N0M0 differentiated thyroid carcinoma.

Article Details

Keywords

TOETVA, Differential thyroid carcinoma

References

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229-263. doi:10.3322/caac. 21834
2. Ito Y, Miyauchi A, Kihara M, Fukushima M, Higashiyama T, Miya A. Overall Survival of Papillary Thyroid Carcinoma Patients: A Single-Institution Long-Term Follow-Up of 5897 Patients. World J Surg. 2018;42(3):615-622. doi:10.1007/ s00268-018-4479-z
3. Matsuzu K, Sugino K, Masudo K, et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg. 2014;38(1):68-79. doi:10.1007/s00268-013-2224-1
4. Xuan Nguyen H, Nguyen HX, Thi Hoang H, Van Le Q. Quality of Life and Surgical Outcome of Transoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA) versus Open Thyroid Surgery: Experience from a Single Center in Vietnam. Journal of Thyroid Research. 2022; 2022:e2381063. doi:10.1155/2022/2381063
5. Ahn J hyuk, Yi JW. Transoral endoscopic thyroidectomy for thyroid carcinoma: outcomes and surgical completeness in 150 single-surgeon cases. Surg Endosc. 2020;34(2):861-867. doi:10. 1007/s00464-019-06841-8
6. Tang L, Qu RW, Park J, Simental AA, Inman JC. Prevalence of Occult Central Lymph Node Metastasis by Tumor Size in Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis. Curr Oncol. 2023;30(8):7335-7350. doi:10.3390/curroncol30080532
7. Xuan HN, Anh TD, Xuan HN, Thai DP, Le Van Q. Occult Central Lymph Node Metastasis in cN0 Papillary Thyroid Carcinoma Patients Undergoing TOETVA Procedure. J Thyroid Res. 2023;2023: 4779409. doi:10.1155/2023/4779409
8. Cappola AR, Mandel SJ. Molecular testing in thyroid cancer: BRAF mutation status and mortality. JAMA. 2013;309(14):1529-1530. doi: 10.1001/jama.2013.3620